

# Drug Delivery Technologies: Nanotechnology



*World Leaders in Health Industry Analysis*



---

**Drug Delivery Technologies: Nanotechnology**

June 2009

ISBN: 978 1 85822 353 7

© Copyright 2009 Espicom Business Intelligence

All rights reserved. No part of this publication may be reproduced or used in any form or by any means graphic, electronic or mechanical, including photocopying, recording, taping or storage in information retrieval systems without the express permission of the publisher.

Every care has been taken to ensure that the information contained in this report is correct. The publisher accepts no liability for decisions made on the basis of information contained herein.

British Library Cataloguing in Publication Data.

A catalogue record for this report is available from the British Library.

# CONTENTS

<b>EXECUTIVE SUMMARY .....</b>	<b>1</b>
<b>INTRODUCTION.....</b>	<b>2</b>
<b>Overview of nanotechnology: past, present &amp; future .....</b>	<b>2</b>
<i>Multifunctional nanotechnology platform .....</i>	<i>3</i>
<b>Nanotechnology: motivators &amp; resisters.....</b>	<b>3</b>
<b>Motivators.....</b>	<b>3</b>
<i>Nanotechnology motivators .....</i>	<i>4</i>
<b>Resisters .....</b>	<b>4</b>
<i>Nanotechnology resisters.....</i>	<i>5</i>
<b>Nanomedicines, formulations and product regeneration.....</b>	<b>5</b>
<i>Failure rates at each stage of clinical drug development.....</i>	<i>5</i>
<b>NANOTECHNOLOGY IN DRUG DELIVERY .....</b>	<b>7</b>
<b>Core nanotechnology used by the pharma industry .....</b>	<b>7</b>
<b>Nano-engineered drugs .....</b>	<b>7</b>
<b>Nano-carriers .....</b>	<b>7</b>
<i>Dendrimer structure.....</i>	<i>8</i>
<i>Liposome structure .....</i>	<i>8</i>
<i>Micelle structure.....</i>	<i>9</i>
<i>Polymeric nanoparticle structure - Abraxane.....</i>	<i>10</i>
<b>Current therapeutic applications of nanotechnology in drug delivery.....</b>	<b>11</b>
<b>Leading brands that utilise nanotechnology delivery.....</b>	<b>11</b>
<i>Nanotechnology-enabled approved drugs .....</i>	<i>11</i>
<b>Future commercial applications &amp; opportunities.....</b>	<b>13</b>
<b>STRATEGIES OF DRUG DELIVERY COMPANIES .....</b>	<b>14</b>
<b>Leading nanotechnology drug delivery companies.....</b>	<b>14</b>
<i>Leading nanotechnology-enabled drug delivery companies.....</i>	<i>14</i>
<b>Partnerships &amp; acquisitions .....</b>	<b>17</b>
<b>Strategic development &amp; commercialisation partnerships and joint ventures.....</b>	<b>17</b>
<b>Mergers, acquisitions, start ups &amp; spin offs .....</b>	<b>17</b>
<i>Recent partnerships &amp; acquisitions in the nanotechnology field.....</i>	<i>18</i>
<b>Intellectual Property.....</b>	<b>20</b>
<i>Nanotechnology patents .....</i>	<i>20</i>
<b>THE NANOTECHNOLOGY MARKET .....</b>	<b>22</b>
<b>Now 2009 .....</b>	<b>22</b>
<i>Leading approved nano-enabled product sales .....</i>	<i>22</i>
<i>Leading companies developing nano-enabled product sales .....</i>	<i>23</i>
<b>Future 2018 .....</b>	<b>23</b>
<i>Novel nano-enabled product sales .....</i>	<i>24</i>
<i>Global nano-enabled product sales .....</i>	<i>24</i>
<b>COMPETITOR ANALYSIS .....</b>	<b>25</b>
<b>Movers &amp; Shakers: Cutting edge or losing their grip.....</b>	<b>25</b>
<i>Movers &amp; shakers in nanotechnology drug delivery systems.....</i>	<i>26</i>
<b>COMPANY PROFILES.....</b>	<b>27</b>
<b>Abraxis Bioscience (www.abraxisbio.com).....</b>	<b>27</b>
<b>Proprietary delivery technology.....</b>	<b>27</b>
<i>Abraxis Protosphere - nab technology.....</i>	<i>27</i>
<b>Applications in the pharma industry.....</b>	<b>27</b>
<b>Management/technical expertise .....</b>	<b>27</b>
<b>Competition within the delivery technology sector .....</b>	<b>27</b>

Products in development/approved utilising the delivery technology.....	28
<i>Abraxis' product pipeline</i> .....	28
Sales forecasts of products utilising the delivery technology .....	28
<i>Abraxis' sales forecasts</i> .....	28
Competitor Ratio Analysis .....	28
<b>Access Pharmaceuticals (www.accesspharma.com) .....</b>	<b>29</b>
Proprietary delivery technology .....	29
<i>ProLindac nanoparticulate prodrug</i> .....	29
<i>Cobalamin coated nanoparticles</i> .....	30
Applications in the pharma industry.....	30
Management/technical expertise .....	30
Competition within the delivery technology sector .....	31
Products in development/approved utilising the delivery technology.....	31
<i>Access Pharmaceuticals product pipeline</i> .....	31
Sales forecasts of products utilising the delivery technology .....	31
<i>Access' sales forecasts</i> .....	31
Competitor Ratio Analysis .....	32
<b>AlphaRx Corporation (www.alpharx.com) .....</b>	<b>33</b>
Proprietary delivery technology .....	33
<i>Nanoparticle targeted delivery &amp; uptake</i> .....	33
Applications in the pharma industry.....	33
Management/technical expertise .....	34
Competition within the delivery technology sector .....	34
Products in development/approved utilising the delivery technology.....	34
<i>AlphaRx' product pipeline</i> .....	34
Sales forecasts of products utilising the delivery technology .....	34
<i>AlphaRx' pharmaceuticals sales</i> .....	35
Competitor Ratio Analysis .....	35
<b>ALZA Corporation (www.alza.com) .....</b>	<b>36</b>
Proprietary delivery technology .....	36
Applications in the pharma industry.....	36
Management/technical expertise .....	36
Competition within the delivery technology sector .....	36
Products in development/approved utilising the delivery technology.....	36
Sales forecasts of products utilising the delivery technology .....	36
<i>ALZA's drug delivery sales</i> .....	36
Competitor Ratio Analysis .....	37
<b>Aphios Corporation (www.aphios.com).....</b>	<b>38</b>
Proprietary delivery technology .....	38
Applications in the pharma industry.....	38
Management/technical expertise .....	38
Competition within the delivery technology sector .....	38
Products in development/approved utilising the delivery technology.....	38
<i>Aphios' product pipeline</i> .....	39
Sales forecasts of products utilising the delivery technology .....	39
Competitor Ratio Analysis .....	39
<b>APR Applied Pharma Research (www.apr.com) .....</b>	<b>40</b>
Proprietary delivery technology .....	40
Applications in the pharma industry.....	40
Management/technical expertise .....	40
Competition within the delivery technology sector .....	40

Products in development/approved utilising the delivery technology..... 41

*APR's product pipeline* ..... 41

Sales forecasts of products utilising the delivery technology ..... 41

Competitor Ratio Analysis ..... 41

**BioSante Pharmaceuticals (www.biosantepharma.com) ..... 42**

Proprietary delivery technology ..... 42

Applications in the pharma industry..... 42

Management/technical expertise ..... 42

Competition within the delivery technology sector ..... 43

Products in development/approved utilising the delivery technology..... 43

*BioSante's CaP product pipeline*..... 43

Sales forecasts of products utilising the delivery technology ..... 44

*BioSante's drug delivery sales* ..... 44

Competitor Ratio Analysis ..... 44

**Calando Pharmaceuticals (www.calandopharma.com) ..... 45**

Proprietary delivery technology ..... 45

*Schematic of cyclodextrin polymeric nanoparticles* ..... 45

Applications in the pharma industry ..... 45

Management/technical expertise ..... 45

Competition within the delivery technology sector ..... 46

Products in development/approved utilising the delivery technology..... 46

*Calando's product pipeline*..... 46

Sales forecasts of products utilising the delivery technology ..... 46

*Calando's sales forecasts* ..... 46

Competitor Ratio Analysis ..... 46

**Camurus AB (www.camurus.se) ..... 47**

Proprietary delivery technology ..... 47

Applications in the pharma industry..... 47

Management/technical expertise ..... 47

Competition within the delivery technology sector ..... 47

Products in development/approved utilising the delivery technology..... 47

*Camurus AB's product pipeline*..... 48

Sales forecasts of products utilising the delivery technology ..... 48

*Camurus AB's drug delivery sales*..... 48

Competitor Ratio Analysis ..... 48

**Cerulean Pharma Inc (www.ceruleanrx.com) ..... 49**

Proprietary delivery technology ..... 49

Applications in the pharma industry..... 49

Management/technical expertise ..... 49

Competition within the delivery technology sector ..... 49

Products in development/approved utilising the delivery technology..... 49

*Cerulean's product pipeline*..... 49

Sales forecasts of products utilising the delivery technology ..... 50

Competitor Ratio Analysis ..... 50

**CytImmune Sciences Inc (www.cytimmune.com) ..... 51**

Proprietary delivery technology ..... 51

*CytImmune's Colloidal Gold Nanoparticle Delivery* ..... 51

Applications in the pharma industry ..... 51

Management/technical expertise ..... 51

Competition within the delivery technology sector ..... 52

Products in development/approved utilising the delivery technology..... 52

<i>CytImmune's product pipeline</i> .....	52
<b>Sales forecasts of products utilising the delivery technology</b> .....	<b>52</b>
<i>CytImmune's sales forecasts</i> .....	52
<b>Competitor Ratio Analysis</b> .....	<b>53</b>
<b>Elan Corporation (www.elan.com)</b> .....	<b>54</b>
Proprietary delivery technology .....	54
Applications in the pharma industry .....	54
Management/technical expertise .....	54
Competition within the delivery technology sector .....	54
Products in development/approved utilising the delivery technology .....	55
<i>Elan's NanoCrystal product portfolio</i> .....	55
<b>Sales forecasts of products utilising the delivery technology</b> .....	<b>55</b>
<i>Elan's drug delivery sales</i> .....	56
<b>Competitor Ratio Analysis</b> .....	<b>56</b>
<b>Enzon Pharmaceuticals, Inc. (www.enzon.com)</b> .....	<b>57</b>
Proprietary delivery technology .....	57
Applications in the pharma industry .....	57
Management/technical expertise .....	57
Competition within the delivery technology sector .....	57
Products in development/approved utilising the delivery technology .....	57
<i>Enzon's product pipeline</i> .....	58
<b>Sales forecasts of products utilising the delivery technology</b> .....	<b>58</b>
<i>Enzon's targeted product sales</i> .....	58
<b>Competitor Ratio Analysis</b> .....	<b>58</b>
<b>Gilead Sciences (www.gilead.com)</b> .....	<b>59</b>
Proprietary delivery technology .....	59
Applications in the pharma industry .....	59
Management/technical expertise .....	59
Competition within the delivery technology sector .....	59
Products in development/approved utilising the delivery technology .....	59
<i>Gilead Sciences' product pipeline</i> .....	59
<b>Sales forecasts of products utilising the delivery technology</b> .....	<b>60</b>
<i>Gilead Sciences' drug delivery sales</i> .....	60
<b>Competitor Ratio Analysis</b> .....	<b>60</b>
<b>Introgen Therapeutics (www.introgen.com)</b> .....	<b>61</b>
Proprietary delivery technology .....	61
Applications in the pharma industry .....	61
Management/technical expertise .....	61
Competition within the delivery technology sector .....	61
Products in development/approved utilising the delivery technology .....	61
<i>Introgen's product pipeline</i> .....	62
<b>Sales forecasts of products utilising the delivery technology</b> .....	<b>62</b>
<i>Introgen's sales forecasts</i> .....	62
<b>Competitor Ratio Analysis</b> .....	<b>62</b>
<b>Mersana Therapeutics (www.mersana.com)</b> .....	<b>63</b>
Proprietary delivery technology .....	63
Applications in the pharma industry .....	63
Management/technical expertise .....	63
Competition within the delivery technology sector .....	63
Products in development/approved utilising the delivery technology .....	63
<i>Mersana's product pipeline</i> .....	63

Sales forecasts of products utilising the delivery technology .....	64
<i>Mersana's sales forecasts</i> .....	64
Competitor Ratio Analysis .....	64
<b>Nano Interface Technology (www.nanointerfacetech.com)</b> .....	<b>65</b>
Proprietary delivery technology .....	65
Applications in the pharma industry.....	65
Management/technical expertise .....	65
Competition within the delivery technology sector .....	65
Products in development/approved utilising the delivery technology.....	65
<i>NITI's product pipeline</i> .....	66
Sales forecasts of products utilising the delivery technology .....	66
Competitor Ratio Analysis .....	66
<b>Nano S Biotechnology GmbH (www.nano-s.com)</b> .....	<b>67</b>
Proprietary delivery technology .....	67
<i>S-Layer Technology Platform</i> .....	67
Applications in the pharma industry.....	67
Management/technical expertise .....	67
Competition within the delivery technology sector .....	68
Products in development/approved utilising the delivery technology.....	68
<i>Nano S' product pipeline</i> .....	68
Sales forecasts of products utilising the delivery technology .....	68
Competitor Ratio Analysis .....	68
<b>NanoBio Corporation (www.nanobio.com)</b> .....	<b>69</b>
Proprietary delivery technology .....	69
Applications in the pharma industry.....	69
Management/technical expertise .....	69
Competition within the delivery technology sector .....	69
Products in development/approved utilising the delivery technology.....	69
<i>NanoBio's product pipeline</i> .....	70
Sales forecasts of products utilising the delivery technology .....	70
<i>NanoBio's drug delivery sales</i> .....	70
Competitor Ratio Analysis .....	70
<b>NanoBioMagnetics (www.nanobmi.com)</b> .....	<b>71</b>
Proprietary delivery technology .....	71
Applications in the pharma industry.....	71
Management/technical expertise .....	71
Competition within the delivery technology sector .....	71
Products in development/approved utilising the delivery technology.....	72
<i>NanoBioMagnetics' product pipeline</i> .....	72
Sales forecasts of products utilising the delivery technology .....	72
Competitor Ratio Analysis .....	72
<b>Nanobiotix (www.nanobiotix.com)</b> .....	<b>73</b>
Proprietary delivery technology .....	73
Applications in the pharma industry.....	73
Management/technical expertise .....	73
Competition within the delivery technology sector .....	73
Products in development/approved utilising the delivery technology.....	73
<i>Nanobiotix' product pipeline</i> .....	73
Sales forecasts of products utilising the delivery technology .....	74
Competitor Ratio Analysis .....	74
<b>NanoCarrier (www.nanocarrier.co.jp)</b> .....	<b>75</b>

<b>Proprietary delivery technology</b> .....	<b>75</b>
<i>Micellar Nanoparticles</i> .....	75
<b>Applications in the pharma industry</b> .....	<b>75</b>
<b>Management/technical expertise</b> .....	<b>76</b>
<b>Competition within the delivery technology sector</b> .....	<b>76</b>
<b>Products in development/approved utilising the delivery technology</b> .....	<b>76</b>
<i>NanoCarrier's product pipeline</i> .....	76
<b>Sales forecasts of products utilising the delivery technology</b> .....	<b>76</b>
<i>NanoCarrier's drug delivery sales</i> .....	77
<b>Competitor Ratio Analysis</b> .....	<b>77</b>
<b>Nanotechnology Victoria, Ltd (www.nanovic.com)</b> .....	<b>78</b>
<b>Proprietary delivery technology</b> .....	<b>78</b>
<b>Applications in the pharma industry</b> .....	<b>78</b>
<b>Management/technical expertise</b> .....	<b>78</b>
<b>Competition within the delivery technology sector</b> .....	<b>78</b>
<b>Products in development/approved utilising the delivery technology</b> .....	<b>78</b>
<i>NanoVic's product pipeline</i> .....	79
<b>Sales forecasts of products utilising the delivery technology</b> .....	<b>79</b>
<b>Competitor Ratio Analysis</b> .....	<b>79</b>
<b>NanoMaterials Technology (www.nanomt.com)</b> .....	<b>80</b>
<b>Proprietary delivery technology</b> .....	<b>80</b>
<i>High Gravity Controlled Precipitation (HCGP) of nanomaterials</i> .....	80
<b>Applications in the pharma industry</b> .....	<b>80</b>
<b>Management/technical expertise</b> .....	<b>80</b>
<b>Competition within the delivery technology sector</b> .....	<b>81</b>
<b>Products in development/approved utilising the delivery technology</b> .....	<b>81</b>
<i>NanoMaterial's product pipeline</i> .....	81
<b>Sales forecasts of products utilising the delivery technology</b> .....	<b>81</b>
<b>Competitor Ratio Analysis</b> .....	<b>81</b>
<b>Nanotherapeutics (www.nanotherapeutics.com)</b> .....	<b>82</b>
<b>Proprietary delivery technology</b> .....	<b>82</b>
<b>Applications in the pharma industry</b> .....	<b>82</b>
<b>Management/technical expertise</b> .....	<b>82</b>
<b>Competition within the delivery technology sector</b> .....	<b>83</b>
<b>Products in development/approved utilising the delivery technology</b> .....	<b>83</b>
<i>Nanotherapeutics' product pipeline</i> .....	83
<b>Sales forecasts of products utilising the delivery technology</b> .....	<b>83</b>
<i>Nanotherapeutics' drug delivery sales</i> .....	84
<b>Competitor Ratio Analysis</b> .....	<b>84</b>
<b>Novavax (www.novavax.com)</b> .....	<b>85</b>
<b>Proprietary delivery technology</b> .....	<b>85</b>
<b>Applications in the pharma industry</b> .....	<b>85</b>
<b>Management/technical expertise</b> .....	<b>85</b>
<b>Competition within the delivery technology sector</b> .....	<b>86</b>
<b>Products in development/approved utilising the delivery technology</b> .....	<b>86</b>
<i>Novavax's product pipeline</i> .....	86
<b>Sales forecasts of products utilising the delivery technology</b> .....	<b>87</b>
<i>Novavax's drug delivery sales</i> .....	87
<b>Competitor Ratio Analysis</b> .....	<b>87</b>
<b>SkyePharma (www.skyepharma.com)</b> .....	<b>88</b>
<b>Proprietary delivery technology</b> .....	<b>88</b>

Applications in the pharma industry.....88

Management/technical expertise .....88

Competition within the delivery technology sector .....89

Products in development/approved utilising the delivery technology.....89

*SkyePharma's product pipeline* .....89

Sales forecasts of products utilising the delivery technology .....89

*SkyePharma's product sales* .....90

Competitor Ratio Analysis .....90

**Spherics (www.spherics.com) .....91**

Proprietary delivery technology .....91

Applications in the pharma industry.....91

Management/technical expertise .....91

Competition within the delivery technology sector .....91

Products in development/approved utilising the delivery technology.....91

*Spheric's product pipeline* .....92

Sales forecasts of products utilising the delivery technology .....92

Competitor Ratio Analysis .....92

**Starpharma (www.starpharma.com) .....93**

Proprietary delivery technology .....93

*Dendrimer nanotechnology*.....93

Applications in the pharma industry.....93

Management/technical expertise .....93

Competition within the delivery technology sector .....94

Products in development/approved utilising the delivery technology.....94

*Starpharma's product pipeline* .....94

Sales forecasts of products utilising the delivery technology .....94

*Starpharma's product sales* .....94

Competitor Ratio Analysis .....95

**APPENDIX 1 .....96**

*Global nanotechnology approved drugs sales 2008-2018*.....96

**APPENDIX 2 .....97**

*Global nanotechnology developmental drugs sales 2008-2018*.....97

**APPENDIX 3 .....98**

Competitor Ratio Analysis Criteria.....98

*Key nanotechnology delivery companies by 2018*.....99

**GLOSSARY ..... 100**

**ACRONYMS..... 103**

**BIBLIOGRAPHY..... 105**

**ENDNOTES..... 105**